IN THE SPOTLIGHT

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Is Immunotherapy Beneficial in Patients with Oncogene-Addicted Non-Small Cell Lung Cancers? A Narrative Review

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Dr Mark Socinski on How Targeted Therapies Have Impacted Lung Cancer Outcomes

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

ICYMI: Alecensa Exhibited Unprecedented Results for Patients with Early-Stage Lung Cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC

Lung cancer biomarker campaign, launched with AstraZeneca, boosts its reach and adds pharma supporters

Lung cancer biomarker campaign, launched with AstraZeneca, boosts its reach and adds pharma supporters

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC

Trial-first for Roche lung cancer ALK inhibitor

Trial-first for Roche lung cancer ALK inhibitor

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer

Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer


Roche claims study success for targeted drug in early lung cancer


Roche claims study success for targeted drug in early lung cancer

A Look at NSCLC and Its Current and Emerging Therapies

A Look at NSCLC and Its Current and Emerging Therapies

dr Liu on the importance of NGS testing in NSCLC

dr Liu on the importance of NGS testing in NSCLC

The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report

The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report

ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma

ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

Medicaid Patients With NSCLC May Be Undertreated With Life-prolonging Targeted Therapies

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Differences in Tumor Biology Could Partly Explain Disparities in Metastatic NSCLC

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial

Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC

Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC

Targeted therapies and expanded access to NGS improve lung cancer decision-making

Targeted therapies and expanded access to NGS improve lung cancer decision-making

Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC

Lorlatinib Improves PFS, Reduces CNS Progression in Advanced ALK+ NSCLC

Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward

Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives

Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives